Therapeutic Strategies in Acromegalic Subjects Treated With Lanreotide 120mg
NCT ID: NCT02698384
Last Updated: 2018-12-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
4 participants
OBSERVATIONAL
2016-01-31
2016-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Treatment naïve or treated subject (whatever the previous treatments except Lanreotide 120mg and radiotherapy) who does not achieve biochemical control in the physician's opinion. Requiring a treatment with Somatostatin analog (SSA)
* Having performed a Magnetic Resonance Imaging (MRI) to evaluate the tumor size within the previous 12 weeks (post-surgery MRI for operated subjects)
* In whom the physician has already decided to initiate a treatment with Lanreotide 120mg as a monotherapy
Exclusion Criteria
* History of radiotherapy for acromegaly
* Subject who requires a surgical intervention for relief of any sign or symptom associated with tumor compression
* Concomitant prolactin hypersecretion requiring a treatment with dopaminergic agonists
* Active neoplastic disease
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ipsen
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ipsen Medical Director
Role: STUDY_DIRECTOR
Ipsen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hoptial Nord
Amiens, , France
Hopital jean Minjoz
Besançon, , France
Hopital Neuro-Cardiologique, Fédération d'Endocrinologie
Bron, , France
Hopital Albert Michallon
La Tronche, , France
Hopital De La Conception
Marseille, , France
Hopital Haut Leveque
Pessac, , France
Hopital Robert Debre
Reims, , France
Hopital Nord
Saint-Etienne, , France
Hopital De Hautepierre
Strasbourg, , France
Hopital Larrey
Toulouse, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A-54-52030-315
Identifier Type: -
Identifier Source: org_study_id